Litigation tracker · Updated monthly

GLP-1 lawsuits + multidistrict litigation status

Live status of the two main GLP-1 mass-tort cases consolidated in federal court. Editorial information only — we do not refer to law firms or charge for case evaluation.

MDL No. 3094consolidated3,127 cases

GLP-1 Receptor Agonist Products Liability Litigation (MDL-3094)

Multidistrict litigation consolidating product-liability claims alleging that GLP-1 medications cause severe gastroparesis, ileus, intestinal obstruction, and gallbladder injury beyond what the labels disclosed at time of prescription.

Court: US District Court, Eastern District of Pennsylvania
Judge: Hon. Karen S. Marston
Filed: 2024-02-02
Defendants: Novo Nordisk Inc., Eli Lilly and Company

Evidence the court has accepted

Gastric-emptying scintigraphy showing delayed emptying ≥30 minutes
Smart-pill or wireless motility capsule study
Endoscopy or imaging documenting obstruction or retained gastric contents
Prescription records confirming GLP-1 use prior to symptom onset

MDL No. 3163consolidated29 cases

Semaglutide NAION (Vision Loss) Litigation (MDL-3163)

Multidistrict litigation alleging that semaglutide (Ozempic, Wegovy) causes non-arteritic anterior ischemic optic neuropathy (NAION) — a rare form of sudden vision loss. Consolidated December 2025.

Court: US District Court, Eastern District of Pennsylvania
Judge: Hon. Karen S. Marston
Filed: 2025-12-09
Defendants: Novo Nordisk Inc.

Evidence the court has accepted

Ophthalmologist diagnosis of NAION
Visual field testing documenting characteristic defect
Optical coherence tomography (OCT) imaging
Documented semaglutide use within 12 months of vision loss onset

Where to get neutral patient help

We do not refer to law firms or accept any compensation for legal-services placement. For neutral patient-facing resources:

Obesity Action Coalition (OAC) — patient resource center + community
PACER (federal court docket) — search by MDL number for original filings
FDA recall + adverse-event tracker →

This is editorial information about ongoing litigation, not legal advice. We are not attorneys, we do not refer to law firms, and we accept no compensation for case placement. For legal advice, consult a licensed attorney in your jurisdiction.